Welcome to our dedicated page for SUPERNUS PHARMACEUTICALS SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SUPERNUS PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SUPERNUS PHARMACEUTICALS's regulatory disclosures and financial reporting.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief scientific officer Padmanabh P. Bhatt reported equity awards on February 18, 2026. He received an option to buy 13,500 shares of common stock and 3,000 restricted stock units, both granted at $0.00 per share as compensation.
The option and RSUs vest in four equal annual installments beginning on February 18, 2027. Following these awards, Bhatt directly holds 14,900 shares of common stock, which includes 392 shares acquired through the company’s employee stock purchase plan, along with the new option and RSU positions.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief medical officer Jonathan Rubin received new equity awards. On February 18, 2026, he was granted an employee stock option for 13,500 shares and 3,000 restricted stock units, both at no exercise cost per the filing.
The option vests in four equal annual installments starting February 18, 2027. Each restricted stock unit converts into one share of common stock and also vests in four equal annual installments beginning on that date. Following these awards, Rubin directly holds 11,284 shares of common stock, including 269 acquired through the employee stock purchase plan.
SUPERNUS PHARMACEUTICALS, INC. reported that SVP and Chief Technical Operations Officer Frank Mottola received new equity awards. He was granted employee stock options for 13,500 shares and 3,000 restricted stock units on February 18, 2026, both at a price of $0.00 per share.
The options vest in four equal annual installments beginning on February 18, 2027. Each restricted stock unit converts into one share of common stock and is settled in stock upon vesting, also in four equal annual installments starting on February 18, 2027. Following these grants, Mottola directly holds 15,724 shares of common stock, which include 228 shares acquired through the company’s employee stock purchase plan, along with the 13,500 options and 3,000 restricted stock units.
SUPERNUS PHARMACEUTICALS, INC. reported that President and CEO Jack A. Khattar received a grant of employee stock options for 341,610 shares on February 18, 2026. The options were awarded as a grant/award acquisition and vest in four equal annual installments beginning on February 18, 2027.
GEMAYEL GEORGES reported acquisition or exercise transactions in this Form 4 filing.
Supernus Pharmaceuticals director Georges Gemayel reported receiving new equity awards. On February 18, 2026, he was granted 2,989 restricted stock units and 4,977 director stock options, both at a price of $0.0000 per unit. The RSUs and options each vest on February 18, 2027.
Supernus Pharmaceuticals director Carrolee Barlow reported equity awards consisting of restricted stock units and stock options. On February 18, 2026, Barlow acquired 2,989 restricted stock units and 4,977 director stock options as compensation awards, with no cash paid per unit or option.
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. Both the restricted stock units and the options vest on February 18, 2027, at which time the restricted stock units will be settled in common stock and the options will become exercisable.
Sensenig Bethany reported acquisition or exercise transactions in this Form 4 filing.
SUPERNUS PHARMACEUTICALS, INC. director Bethany Sensenig received new equity awards in the form of restricted stock units and stock options. She was granted 2,989 restricted stock units, each representing one share of Supernus common stock, and 4,977 director stock options.
The restricted stock units will be settled in common stock when they vest on February 18, 2027. The director stock options also vest on February 18, 2027. These awards increase Sensenig’s equity-based stake in the company but do not involve any open‑market share purchases or sales.
Supernus Pharmaceuticals director Charles W. Newhall III reported equity awards consisting of 2,989 restricted stock units and options for 4,977 shares, both granted on February 18, 2026. Each restricted stock unit converts into one share, and both the RSUs and options vest on February 18, 2027.
Hudson Frederick M. reported acquisition or exercise transactions in this Form 4 filing.
SUPERNUS PHARMACEUTICALS, INC. director Frederick M. Hudson reported equity awards consisting of restricted stock units and stock options. He was granted 2,989 restricted stock units and 4,977 director stock options on February 18, 2026, each at a grant price of $0 per unit or option.
Each restricted stock unit represents one share of Supernus common stock and will be settled in common stock when it vests on February 18, 2027. The stock options also vest on February 18, 2027, giving him the right to buy Supernus common stock in the future, subject to the option terms.